Announced details
International collaborative clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS)
Our research and development project was selected for an AMED open-call program. Capital and personnel relationships: Not disclosed.
A Japanese national research and development agency. Location, representative, capital and year established: Not disclosed.
FDA orphan-drug designation for AML and orphan-drug designation in Japan. Registration number and validity period: Not disclosed.
Currently undetermined because the grant amount and other details have not yet been finalized.
The company does not address Contract Value / Offering price.
AMED open-call information
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib (development code: CTX-712) |
| Counterparty | Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | A Japanese national research and development agency. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | Our research and development project was selected for an AMED open-call program. Capital and personnel relationships: Not disclosed. |
| Applicable area | International collaborative clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS) |
| Registration number and expiry date | FDA orphan-drug designation for AML and orphan-drug designation in Japan. Registration number and validity period: Not disclosed. |
| Impact on Business Performance | Currently undetermined because the grant amount and other details have not yet been finalized. |
| Source | AMED open-call information |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.AMED recognized rogocekib's novel mechanism of action involving changes in RNA splicing, as well as the advanced nature and social significance of its international joint development strategy.